Figure 2.

Clinical and radiological characteristics of RR‐MS patients after alemtuzumab therapy stratified by FcγR polymorphisms. (A) Data for homozygous 158V/V (high‐affinity), homozygous 158F/F and heterozygous 158F/V FcγRIIIA polymorphisms and (B) homozygous 131H/H (high‐affinity), homozygous 131R/R and heterozygous 131H/R FcγRIIA polymorphisms are depicted. For some characteristics not all patient data were available. For the following analyses the n was: 84, NEDA‐3/ FcγRIIIA (1 patient missing, F/F group); 83, MRI stability/ FcγRIIIA (2 patients missing, F/F and V/V groups); 84, NEDA‐3/ FcγRIIA (1 patient missing, R/R group) and 83, MRI stability/ FcγRIIA (2 patients missing, H/R and R/R groups). The remaining analyses were carried out on all 85 patients. Shown are percentages of the respective genotypic groups as bargraphs and absolute numbers of patients in white. Statistical analysis: Two‐sided Fischer’s exact test with Bonferroni correction for multiple testing was applied on absolute patient numbers. A p‐value < .05 was considered statistically significant. Abbreviations: CDP, confirmed disability progression; MRI, magnetic resonance imaging; NEDA, no evidence of disease activity; IAR, infusion‐associated reactions; SAD, secondary autoimmune disease